EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Common sense oncology values to action: a patient-led framework for randomized clinical trial design

Michelle L Tregear, Haydeé C Verduzco-Aguirre, Brian Shkabari iD, Rachel Koven, Henry Scowcroft, Viji Venkatash, Michael D Brundage iD, Runcie C W Chidebe iD, Elizabeth A Eisenhauer iD, Bishal Gyawali iD, Bhawna Sirohi iD, Christopher M Booth iD und 1 weitere

JNCI: Journal of the National Cancer Institute · 2026

DOI: 10.1093/jnci/djag092 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2026. Verfasst von Michelle L Tregear und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Breast Cancer Coalition, Washington, DC, United States. Hauptthemen laut MEDLINE: Research Design, Randomized Controlled Trials as Topic, Medical Oncology, Neoplasms. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Randomized controlled trials are the foundation of oncology drug development, yet increasing concern exists that some prioritize regulatory approval over outcomes that matter to patients. The Common Sense Oncology (CSO) initiative was founded to reorient research toward patient-valued endpoints. The CSO Patient Priorities Working Group sought to codevelop a pragmatic, patient-centered framework articulating values and actions to guide the design, conduct, and reporting of oncology randomized controlled trials.

Methods

A multiphase, mixed-methods process included literature review, thematic analysis, and international stakeholder engagement. Eight focus groups were held between April 2024 and January 2025 with 131 participants across 7 countries, including people with lived cancer experience, advocates, clinicians, and trialists. Feedback from surveys and structured discussions—quantitative ratings and qualitative insights—informed iterative framework refinement.

Results

The final framework defines 9 core values with associated actions: meaningful research question, patient partnerships, informed consent, meaningful benefit, generalizability, optimal comparator arm, minimal participant burden, timely feedback of results, and clear dissemination. All values received high endorsement (median 8-9 on a 9-point numeric rating scale [from 1 (least important) to 9 (most important)]). Qualitative analysis emphasized meaningful endpoints, transparent communication, equitable inclusion, fair compensation, and plain-language consent.

Conclusions

The CSO Values to Action Framework provides a validated, internationally informed structure for trialists, ethics boards, funders, and advocates. It offers a practical tool to align oncology research with what matters most to patients, promoting more ethical, inclusive, and relevant clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignRandomized Controlled Trials as TopicMedical OncologyNeoplasmsHumansFocus GroupsInformed ConsentPatient Participation

Autor:innen und Institutionen

  • National Breast Cancer Coalition, Washington, DC, United States.
  • Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico.
  • Division of Cancer Care and Epidemiology, Sinclair Cancer Research Institute, Kingston, ON, Canada.
  • Patient and Family Advisory Council, Southeast Regional Cancer Program, Kingston Health Sciences Centre, Kingston, ON, Canada.
  • Independent Communications Consultant and Patient Advocate, United Kingdom.
  • The Max Foundation, Mumbai, India.

ORCID-Profile: Brian Shkabari, Michael D Brundage, Runcie C W Chidebe, Elizabeth A Eisenhauer, Bishal Gyawali, Bhawna Sirohi, Christopher M Booth, Christopher G C A Jackson

Zitieren

APA

Tregear, M. L., Verduzco-Aguirre, H. C., Shkabari, B., Koven, R., Scowcroft, H., Venkatash, V., Brundage, M. D., Chidebe, R. C. W., Eisenhauer, E. A., Gyawali, B., Sirohi, B., Booth, C. M., & Jackson, C. G. C. A. (2026). Common sense oncology values to action: a patient-led framework for randomized clinical trial design. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag092

Vancouver

Tregear ML, Verduzco-Aguirre HC, Shkabari B, Koven R, Scowcroft H, Venkatash V, et al. Common sense oncology values to action: a patient-led framework for randomized clinical trial design. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djag092

BibTeX
@article{Tregear2026,
  author = {Tregear, Michelle L and Verduzco-Aguirre, Haydeé C and Shkabari, Brian and Koven, Rachel and Scowcroft, Henry and Venkatash, Viji and Brundage, Michael D and Chidebe, Runcie C W and Eisenhauer, Elizabeth A and Gyawali, Bishal and Sirohi, Bhawna and Booth, Christopher M and Jackson, Christopher G C A},
  title = {Common sense oncology values to action: a patient-led framework for randomized clinical trial design},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  doi = {10.1093/jnci/djag092}
}
Kostenlos starten →